Clinical Trials Logo
  1. Home
  2. Lung Cancer Stage III
  3. NCT06086574

Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer — VIGILANCE  

Lung Cancer Stage III Clinical Trial

Official title:
Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer

Clinical Trial Summary

In stage 3 NSCLC, treatment and follow-up are generally performed in a 'one-size-fits-all' manner. In the setting of metastatic lung cancer there has been considerable success identifying biomarkers, which allow treatments to be tailored and lead to more personalised medicine. In patients with stage 3 disease there exists a significant unmet clinical need for equivalent biomarkers to guide treatment decisions such as to identify poor responders, predict benefit from treatment and diagnose relapse before standard of care imaging. Recent advances have made it possible to detect and quantify circulating-tumour DNA in peripheral blood of patients with stage 3 NSCLC, a promising prognostic biomarker and a measure of minimal residual disease. In addition, the information contained in routine medical images and electronic patient reported outcome measure (ePROM) questionnaires can add further predictive power to circulating tumour DNA and other clinical factors to determine patient's outcome. There is scope to integrate biomarkers in treatment decision algorithms aiming to make personalised treatment modifications (e.g. decision to treat with immunotherapy or not). VIGILANCE is a highly exploratory observational study to understand how these biomarkers might inform a future hypothesis driven interventional study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06086574
Study type Observational
Source University of Manchester
Contact
Status Recruiting
Phase
Start date March 24, 2023
Completion date September 24, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06003075 - Induction Chemo-Nivo in Unresectable Stage III NSCLC Phase 2
Enrolling by invitation NCT04305613 - Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
Not yet recruiting NCT05994339 - Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer Phase 2/Phase 3
Not yet recruiting NCT06060964 - Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management Early Phase 1
Recruiting NCT04991025 - Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery Phase 2
Recruiting NCT06111807 - Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Completed NCT04825912 - Resilience Measurement in Older Adults With Late-Stage Lung Cancer N/A
Active, not recruiting NCT03141359 - Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC Phase 2
Recruiting NCT03872661 - Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC Phase 2
Not yet recruiting NCT05358691 - A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants Phase 1
Active, not recruiting NCT04364776 - Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.
Recruiting NCT05258448 - COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)
Recruiting NCT05996263 - Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)
Active, not recruiting NCT04003246 - Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer Phase 2
Completed NCT04057196 - Self-System Therapy for Older Adults With Lung Cancer N/A